JP2022531242A5 - - Google Patents
Info
- Publication number
- JP2022531242A5 JP2022531242A5 JP2021564531A JP2021564531A JP2022531242A5 JP 2022531242 A5 JP2022531242 A5 JP 2022531242A5 JP 2021564531 A JP2021564531 A JP 2021564531A JP 2021564531 A JP2021564531 A JP 2021564531A JP 2022531242 A5 JP2022531242 A5 JP 2022531242A5
- Authority
- JP
- Japan
- Prior art keywords
- hvem
- seq
- cdr
- drug
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061345A JP2025096366A (ja) | 2019-04-29 | 2025-04-02 | 抗ｈｖｅｍ抗体およびそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839841P | 2019-04-29 | 2019-04-29 | |
| US62/839,841 | 2019-04-29 | ||
| US202062965921P | 2020-01-26 | 2020-01-26 | |
| US62/965,921 | 2020-01-26 | ||
| PCT/IL2020/050479 WO2020222235A1 (en) | 2019-04-29 | 2020-04-28 | Anti-hvem antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061345A Division JP2025096366A (ja) | 2019-04-29 | 2025-04-02 | 抗ｈｖｅｍ抗体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531242A JP2022531242A (ja) | 2022-07-06 |
| JP2022531242A5 true JP2022531242A5 (https=) | 2023-05-11 |
Family
ID=73029699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564531A Pending JP2022531242A (ja) | 2019-04-29 | 2020-04-28 | 抗ｈｖｅｍ抗体およびそれらの使用 |
| JP2025061345A Pending JP2025096366A (ja) | 2019-04-29 | 2025-04-02 | 抗ｈｖｅｍ抗体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061345A Pending JP2025096366A (ja) | 2019-04-29 | 2025-04-02 | 抗ｈｖｅｍ抗体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220227879A1 (https=) |
| EP (1) | EP3962956A4 (https=) |
| JP (2) | JP2022531242A (https=) |
| KR (1) | KR20220038594A (https=) |
| CN (1) | CN114026124B (https=) |
| AU (1) | AU2020265142A1 (https=) |
| BR (1) | BR112021021645A2 (https=) |
| CA (1) | CA3135536A1 (https=) |
| IL (1) | IL287690A (https=) |
| SG (1) | SG11202112002SA (https=) |
| WO (1) | WO2020222235A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220128363A (ko) * | 2019-12-24 | 2022-09-20 | 제이제이피 바이오로직스 에스피. 제트 오.오. | 항-인간 hvem(tnfrsf14) 항체 및 그의 용도 |
| WO2022074648A1 (en) | 2020-10-05 | 2022-04-14 | 4C Biomed Limited | Marker for response to pd-1/pd-l1 immunotherapy |
| KR102827269B1 (ko) * | 2020-12-15 | 2025-06-30 | (주)메디톡스 | 항-ｈｖｅｍ 항체, 및 이와 관련된 조성물 및 방법 |
| EP4265639A2 (en) | 2020-12-15 | 2023-10-25 | Medytox Inc. | Anti-hvem antibody, and composition and method associated with same |
| US20240317871A1 (en) | 2020-12-30 | 2024-09-26 | Immunomic Therapeutics, Inc. | Anti-HVEM Antibodies |
| WO2022192358A1 (en) * | 2021-03-10 | 2022-09-15 | Ludwig Institute For Cancer Research Ltd | Anti-tem1 antibodies and antigen-binding portions thereof |
| US20240317873A1 (en) * | 2021-03-16 | 2024-09-26 | City Of Hope | Anti-hvem antibodies |
| WO2022208505A1 (en) * | 2021-04-01 | 2022-10-06 | 4C Biomed Limited | Enhanced anti-hvem antibodies and use thereof |
| CN116715769B (zh) * | 2022-05-26 | 2024-06-25 | 四川大学 | 抗hvem抗体、制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| WO2010006071A1 (en) * | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
| WO2014183885A1 (en) * | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| WO2016172537A1 (en) * | 2015-04-23 | 2016-10-27 | The Trustees Of The University Of Pennsylvania | Compositions to disrupt protein kinase a anchoring and uses thereof |
| EP3464360B1 (en) * | 2016-05-27 | 2025-11-12 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| MX2019007963A (es) * | 2017-01-06 | 2019-10-21 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf. |
-
2020
- 2020-04-28 BR BR112021021645A patent/BR112021021645A2/pt unknown
- 2020-04-28 JP JP2021564531A patent/JP2022531242A/ja active Pending
- 2020-04-28 WO PCT/IL2020/050479 patent/WO2020222235A1/en not_active Ceased
- 2020-04-28 CA CA3135536A patent/CA3135536A1/en active Pending
- 2020-04-28 KR KR1020217038056A patent/KR20220038594A/ko active Pending
- 2020-04-28 AU AU2020265142A patent/AU2020265142A1/en active Pending
- 2020-04-28 EP EP20798692.8A patent/EP3962956A4/en active Pending
- 2020-04-28 CN CN202080045427.7A patent/CN114026124B/zh active Active
- 2020-04-28 US US17/607,189 patent/US20220227879A1/en active Pending
- 2020-04-28 SG SG11202112002SA patent/SG11202112002SA/en unknown
-
2021
- 2021-10-28 IL IL287690A patent/IL287690A/en unknown
-
2025
- 2025-04-02 JP JP2025061345A patent/JP2025096366A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531242A5 (https=) | ||
| JP7844558B2 (ja) | リンパ球における阻害経路の中和 | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| JP7408814B2 (ja) | 抗－ｌｉｌｒｂ１抗体およびその用途 | |
| EP2812022A1 (en) | Cancer treatment and monitoring methods using ox40 agonists | |
| US20220235134A1 (en) | Anti-b7-h3 antibodies | |
| JP2021523213A (ja) | 癌を治療する方法 | |
| RS64977B1 (sr) | Nova anti-pd-l1 antitela | |
| KR20220005627A (ko) | 면역반응의 조절을 위한 방법 및 항체 | |
| US20220162310A1 (en) | Antibody to tigit and use thereof | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| JP2022531242A (ja) | 抗ｈｖｅｍ抗体およびそれらの使用 | |
| WO2017072716A1 (en) | Prognostic method | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| WO2020257789A2 (en) | Anti-tim-3 antibodies | |
| JP7140403B2 (ja) | Ｌｉｇｈｔに結合する抗原結合分子 | |
| JP2023510429A (ja) | 抗ガレクチン－９抗体およびその使用 | |
| CN119278213A (zh) | 针对ctla-4的抗体及其使用方法 | |
| JP2020508636A (ja) | ＩＦＮ−γ誘導性制御性Ｔ細胞転換性抗癌（ＩＲＴＣＡ）抗体およびその使用 | |
| US20240415889A1 (en) | Molecules that bind to cd94/nkg2a heterodimer polypeptides | |
| EP3887399A1 (en) | Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer | |
| JP2025541340A (ja) | Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用 | |
| JP2025535502A (ja) | 抗ｗｔ１／ｈｌａ抗体及びその使用 | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 | |
| JP2024514255A5 (https=) |